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1. INTRODUCTION 
Proliferation is an important feature of malignant tumors, including breast cancer [1-4]. 
Various methods have been established for its quantification, including mitotic index 
determination, measurement of S-phase fraction (SPF) by flow cytometry, counting of 
argyrophilic nucleolar organizer regions (AgNORs), positron emission tomography (PET) and 
immunohistochemistry of proliferation–associated antigens. Beresford et al. have highlighted 
the limitations of many of these new methods and have suggested Ki-67 
immunohistochemistry to be the standard proliferation assay due to its simplicity and wide 
availability [4]. This protein is expressed in all phases of cell cycle, except G0 [5, 6] (Figure 
1).  
 
Figure 1 Expression of Ki-67 protein during the cell cycle 
This feature makes it the best marker to be detected by immunohistochemistry in 
different malignant tumors including breast carcinoma. Proliferating tumor cells show 
positive nuclear reaction with anti-Ki-67 antibodies. The pathologic report generally refers to 
the percentage of positive tumor cells (Ki-67 labeling index, LI).  
   Different studies have demonstrated that a high Ki-67 LI indicates an increased risk of 
recurrence [7-9], metastasis [7, 8, 10-15] and faster progression of the disease. Because of this 
prognostic effect, Ki-67 LIs have been used to tailor patients’ adjuvant treatment. There are 
different previously proposed cut-off values of Ki-67 LI which have been recommended for 
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the indication of chemotherapy for certain patients suffering of breast cancer [8, 12, 16-18]. 
Ki-67 expression has not only prognostic value, but may also be predictive of the response to 
neoadjuvant therapy as suspected by Fasching et al. [8] and by Yerushalmi et al. [10], who 
analyzed the results of different studies looking for the predictive value of Ki-67 LI in case of 
neoadjuvant chemotherapy. In these studies, better response (complete pathological response / 
pCR or complete clinical response / cCR) has been reported in breast cancers with higher 
proliferative activity treated with neoadjuvant chemotherapy [19-24]. Luprosi et al. have also 
found that pCR is in connection with high Ki-67 LI, although the predictive value of this 
marker was not verified [1].  Recent recommendations (including St. Gallen International 
Breast Cancer Conference, 2013) contain Ki-67 evaluation as the part of the routine 
diagnostic procedures although its predictive potential has not yet been proven unequivocally 
in case of neoadjuvant chemotherapy [25-28].  
   Owing to the clinical relevance of Ki-67 LI mentioned above, the reproducibility of its 
evaluation is of obvious importance. The relatively subjective determination of Ki-67 LI can 
lead to a high degree of interobserver variability. There are pathologists who estimate the 
percentage of nuclear staining, whereas others count the number of positive cells in different 
fields of tumor area [1, 29]. The protein has a differential expression during the cell cycle, 
peaking during the M phase, and being much lower during G1 and S phases [10]. Some of the 
labeled cells undergo apoptosis, whereas others remain in one of the gaps (G1 or G2), and still 
others progress to mitosis. This differential expression is one limiting factor in assessing the 
proportion of immunostained cells, as the intensity the evaluating pathologist or software will 
include as positive is variable (Figure 2).  
 
Figure 2 Variable nuclear staining intensity of individual tumor cells with Ki-67  
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Beside variations of expression intensity mentioned above, there are also other factors 
that may influence the evaluation, such as tissue fixation or tissue processing. Tumor areas 
may show significant heterogeneity of proliferation and Ki-67 labeling. While it is common to 
see higher proliferation rates at the periphery of breast cancers, even the periphery may have 
an uneven distribution of positive cells, or areas anywhere in the tumor may proliferate more 
than others, leading to the appearance of so called “hot spots” [18]. There is no consensus 
whether Ki-67 staining evaluation should only consider the hot spots if present, just include 
them in a general count or avoid them altogether. Human or technical performance may also 
generate interobserver variability. 
At this time there are no standardized methods for the elimination of the different 
previously mentioned factors influencing the Ki-67 LI, although efforts have been made 
towards standardization (Table 1) [18]. 
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Table 1 Condensed summary of the recommendations by the International Ki-67 in Breast 
Cancer working group [18] 
PREANALYTICAL 
 Assessment can be done on either core needle biopsies or whole sections from 
resection specimens. Tissue microarrays are not recommended for quantification. 
 Fixation should be in neutral buffered formaline with avoidance of previous freezing 
of the tissues (frozen sections), other fixatives and decalcination in EDTA or acid. 
 Ideally fixation should start rapidely (especially if image analysis is planned), but 
delays up to 20-80 minutes did not abolish staining. 
 Storing of material in paraffin embedded blocks is preferred over unstained sections 
on slides because antigenicity may be lost after 3 months or longer (prolongued exposure of 
the cut surfaces to air is to be avoided) 
 
ANALYTICAL 
 Antigen retrieval is mandatory. (Microwave processing is recommended). 
 MIB-1 antibody recommended over others. 
 Counterstaining of all negative nuclei is important. 
 
INTERPRETATIONAL 
 Scoring should involve the determination of the percentage of positive cells (without 
consideration of staining intensity) in an area with adequate nuclear staining. 
 Considering the average score over the section is recommended (in Table 1 of the 
publication)
5
. In contrast, in the text, the recommendation is: Counting in at least 3 random 
high-power magnification (x40) fields if the staining is homogenous. Counting in 3 high-
power fields at the edge of the tumour if heterogenous staining results from an increasing 
gradient toward the periphery of the tumor (with the exception of comparative counts with 
previous core biopsies, where counting over the section should be performed). If hot spots are 
present, average scoring over the whole area is to be followed (meantime recommendation).  
 Where scoring all cells is not practical, counting the percentage of positive cells on the 
basis of 1000 cells (500 cells as the absolute minimum) in an area representative of the whole 
section is the recommendation. 
 
DATA ANALYSIS RELATED 
 No recommendation. Cut-offs shoud be selected on the basis of the clinical context 
(e.g. prognostication, response to therapy prediction… etc) and end-points should be 
independently validated with similar design and analogous end-points. 
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2. AIMS 
2.1. To analyze the reproducibility of the Ki-67 expression levels by types of 
antibody and investigators in core-biopsy samples of breast cancer patients. 
2.2. To investigate how the use of a standardized, partially digitalized counting 
method could affect reproducibility of determining the Ki-67 LI. 
2.3. To evaluate the distribution of Ki-67 LIs in breast carcinomas diagnosed at 
different institutions by different pathologists using the method reflecting their daily practice.   
2.4. To compare different therapeutic response categories with different Ki-67 
evaluation methods in the cases previously analyzed for reproducibility. Within the frames of 
this latter analysis, to explore whether there was a Ki-67 evaluation method (among the 
previously used ones) which could be particularly recommended (due to its superiority) or 
rejected (due to its inferiority) in daily practice, and to look for a potential cut-off value which 
could separate  tumors with high or low proliferation activity before neoadjuvant therapy.  
15 
 
3. PATIENTS AND METHODS 
3.1 REPRODUCIBILITY AND CORRELATION ANALYSIS OF THE KI-67 
EXPRESSION LEVELS BY TYPES OF ANTIBODY AND INVESTIGATORS 
Core-biopsy samples of patients with operable T2≥3 cm or T3-4 and/or N1-2 and M0 
breast cancer candidate for neoadjuvant docetaxel-epirubicin with/without capecitabine 
chemotherapy were retrospectively analyzed [30].   Samples had been taken between January 
2003 and December 2011, at the Department of Radiology, University of Szeged or Bács-
Kiskun County Teaching Hospital. The tumor samples were fixed in buffered formalin and 
embedded in paraffin. Samples were routinely stained with hematoxylin and eosin (HE) and 
routinely immunostained for estrogen receptor (ER), progesterone receptor (PR), HER-2 and 
topoisomerase II-alpha. For the purpose of this study they were immunostained for Ki-67 with 
the following 3 antibodies: SP6 (monoclonal rabbit antibody, Hisztopatologia Kft., Pécs, 
Hungary), B56 (monoclonal mouse antibody, Hisztopatologia Kft., Pécs, Hungary) and MIB-
1 (monoclonal mouse antibody, Dako, Glostrup, Denmark). Wet antigen retrieval consisted of 
pretreatment of all samples in microwave oven in a citrate buffer with pH6 for 30, 30 and 50 
minutes in case of MIB-1, B56 and SP6, respectively. All antibodies were diluted at 1:100. 
Expression of Ki-67 was determined using Dako EnVision FLEX/HRP, DAB+ Chromogen 
(Dako, Glostrup, Denmark). 
All samples were assessed independently by 3 pathologists at high-power magnification 
(X400). The proportion of Ki-67 positive cells was established with 5% accuracy; therefore 
only values ending with 5 or 0 were recorded. Each observer was asked to use his/her daily 
evaluation approach to quantify the proportion of Ki-67 positive cells and to perform the 
evaluation of all cases stained with one antibody at first, followed by all cases stained with the 
second and third antibody in order to avoid bias arising from remembering the LI of a given 
sample. The assessments were done twice with an interval of at least two months between the 
two evaluations. Each investigator’s results were analyzed for all pairs of antibodies, and the 
results of the different antibodies for all pairs of investigators. To assess how the parameters 
correlate with each other, Spearman’s rank correlation was used in these pairwise analyses. 
Similarly, supposing the ideal linear relationship between Ki-67 LI values, Pearson’s 
coefficients were also calculated for the same pairs. To investigate the influence of the 
observers and the antibody on the Ki-67 LI value further, two-way ANOVA was also 
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performed. The computations were done with the statistical software package SPSS 15.0 for 
Windows (SPSS Inc., Chicago, Illinois). Ki-67 scores were also divided into four quarters (0-
25%, 26-50%, 51-75% and 76-100% Ki-67 LI) to allow categorical data analyses (Figure 3). 
 
Figure 3 Examples of tumor samples belonging to each quarter category of staining (1-
25%: A, B, C; 25-50%: D, E, F; 51-75%: G, H, I; 76-100%: J, K, L) of Ki-67 positive cells on 
the basis of majority opinion, immunostained with the three different Ki-67 antibodies (SP6: 
A, D, G, J; B56: B, E, H, K; MIB-1: C, F, I, L) (x20 magnification) 
 
 Four equally sized categories were arbitrarily chosen to limit their number and to allow 
a better analysis of the consistency of rating into a given category. As the 15% limit has been 
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proposed as a cut-off for the low proliferation category and 30% for the high proliferative 
category, grouping according to these two marginal values (into three categories of unequal 
size) was also evaluated. Interobserver, interreagent and intraobserver agreements were 
assessed with kappa statistics according to Fleiss [31]. Interobserver reproducibility was also 
evaluated by determining pairwise weighted kappa values [31]. These weighted kappas do not 
only take into account the classification into another category (non-agreement) but also give 
weigh to the “distance” between the ordinal categories that have been used for classifying the 
Ki-67 values (e.g. having two ratings into neighboring categories is better than having them 
into categories separated by another category.) The kappa values were interpreted as 
reflecting slight (0-0.2), fair (0.21-0.4), moderate (0.41-0.6), substantial (0.61-0.8) and almost 
perfect (>0.8) agreement between observations according to Landis and Koch [32]. 
 
3.2 INVESTIGATION OF A STANDARDIZED, PARTIALLY DIGITALIZED 
COUNTING METHOD 
In this part of the study, the same immunostained core biopsy samples were used as the 
ones described in section 3.1. Microphotographs were taken of each immunostained slide of 
the core biopsies at an identical magnification (x200). The hot-spot area was photographed in 
all cases where such a hot spot could be identified. More than one photograph was taken of 
each sample (range 2 to 4) and the best was selected for the study. The pictures were entered 
in a Microsoft PowerPoint file. Four different investigators first determined the Ki-67 LI by 
estimating the proportion of stained cells with 5% precision in the same areas (i.e. the same 
digital image displayed on a screen). No counting was involved in this assessment. Time 
needed for the evaluation was recorded in series of cases for all investigators. In a second 
round, a uniform grid composed of equidistant parallel horizontal lines was laid on all digital 
images (Figure 4), previously used for estimation.  
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Figure 4 An example of the digital pictures analyzed. A: image used for estimating the 
Ki-67 LI by eyeballing; B: the same image with parallel grid lines laid over delineates the 
stained and unstained cells (those touching the lines or crossed by them) to be considered 
when counting. 
The observers were asked to count the tumor cells crossed by the lines or touching the 
lines. The lines of the grid can be followed and the touching or crossed cells can be recorded 
(counted) continuously without the doubt of double counting or omitting single cells. Both 
immunohistochemically negative and positive nuclei were counted. Non-cancerous cells 
(stromal elements, lymphocytes etc.) were ignored as much as possible. The ratio of positive 
cells was derived from these values. In further analyses, rounded values (to the next integer) 
were used. Evaluation time was also recorded for this method. In all cases, the participating 
pathologists were asked to consider positive any cell with a brown (stained) rather than blue 
(unstained) hue. Comparisons were performed between the estimated and counted values of 
each investigator. Different investigators’ values were also compared with each other. Kappa 
statistics were used to evaluate the interobserver reproducibility regarding estimation and 
counting. The following cut-off values were used (taking the values mentioned by the St 
Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer in 
2009): 0-15%, 16-30% and >30%. Beside this categorization, Ki-67 values were divided into 
four quarters (0-25%, 26-50%, 51-75% and 76-100% Ki-67 LI). Kappa values were 
calculated according to Fleiss [31] and were interpreted as reflecting slight (0-0.2), fair (0.21-
0.4), moderate (0.41-0.6), substantial (0.61-0.8) and almost perfect (>0.8) agreement between 
observations according to Landis and Koch [32].  Spearman and Pearson correlation 
analyses were also used in order to compare the intra- and interobserver estimated and 
calculated values. Coefficients were categorized as follows: values between 0.9-1 show 
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excellent, 0.75-0.9 good, 0.5-0.75 moderate, 0.25-0.5 week correlation, whereas values 
between 0.0-0.25 reflect lack of correlation.  Comparisons were made for each antibody alone 
(30 values per observer) and for the three different antibodies combined (90 values per 
observer) for each pair of investigators. The analyses were performed both for the estimated 
and the calculated values, using software package SPSS 15.0 for Windows (SPSS Inc., 
Chicago, Illinois). 
3.3 EVALUATION OF THE DISTRIBUTION OF KI-67 LIs IN BREAST 
CARCINOMAS DIAGNOSED AT DIFFERENT INSTITUTIONS 
Contributors were asked to give the Ki-67 values of approximately 100 consecutive 
breast cancers where the staining was performed. Additional information collected in parallel 
included the ER, PR and HER2 status, the age of the patient, the histological type and grade 
of the tumor, the mitotic score component of the combined histological grade and the 
specimen type on which the Ki-67 values were determined. In a questionnaire, data about 
details of staining and evaluation were also collected. In a second round, another 
questionnaire specifically assessed the relation of the assessors to the recommendations of the 
International Ki-67 in Breast Cancer Working Group (Table 1) [18]. Data were collected 
between December 2012 and March 2013. 
3.4 DIFFERENT METHODS OF PRETREATMENT KI-67 LABELING INDEX 
EVALUATION IN CORE BIOPSIES OF BREAST CANCER PATIENTS TREATED 
WITH NEOADJUVANT CHEMOTHERAPY AND THEIR RELATION TO RESPONSE 
TO THERAPY 
Core-biopsy samples described in section 3.1 and 3.2 were chosen by considering 
regression of the primary tumor after neoadjuvant chemotherapy. All patients received 
combination chemotherapy containing docetaxel and an anthracycline (epirubicin for 29 and 
doxorubicin for one patient) with or without capecitabine [30]. Details on clinical and 
pathologic information of patients are summarized in Table 2. 
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Table 2 Clinical and pathological data of patients selected for the study in the three 
regression groups  
 
 
* The patient had a pretreatment sentinel lymph node biopsy yielding 2 metastatic sentinel 
nodes. 
 
 
Three categories were defined: no regression (or progression), partial regression 
(histological signs of regression) and pathological complete regression (no residual invasive 
tumor). Each category included different types of breast carcinoma regarding histological 
  NO  REG RESSION   
  
n=10  
PARTIAL REG RESSION   
  
n=10   
COMPLETE   
REGRESSION   
n=10   
Type of chemotherapy        
    TE  3  2  5  
    TEX   7  8  4  
    TAC  0  0  1  
cT        
    1  0  1  1  
    2  1  6  5  
    3  6  2  2  
    4  3  1  2  
cN         
    0  2  3  1*  
    1  2  1  6  
    2  6  5  2  
    3  0  1  1  
FNA (lymph node)        
    positive   4  4  3  
    not performed   6  6  7  
Pathological data    
ER  -   PR  -   HER - 2 +   1  0  3  
ER + PR +   
HER - 2  -   
4  6  1  
ER+ PR  -   1  0  0  
ER  -   PR  -   4  4  6  
Grade 2   3  3  1  
Grade 3   7  7  9  
invasive ductal   10  8  10  
invasive lobular   0  2  0  
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subtype, grade (G), hormone receptor (HR) and HER-2 status (Table 2). Histological response 
was assessed according to the European guidelines for quality assurance in breast cancer 
screening and diagnosis [33]. Each group consisted of 10 samples. 
The previously mentioned three methods described in section 3.1 and 3.2 (counting on 
glass slide - method 1; counting on digital images – method 2; estimation on digital images – 
method 3) were completed with a fourth, in which the proportion of Ki-67 labeled cells was 
estimated by eyeballing on the glass slides – method 4. The same four investigators estimated 
the proportion of positive tumor cells on the slides by quick inspection of the slides, without 
counting. The average Ki-67 LIs of the respective 10 cases of all observers, antibodies and 
assessment methods were used for comparisons of clinical outcomes (tumor regression 
categories). The Kruskal-Wallis test and analyses of variance (one-way and two-way 
ANOVA) were performed to investigate the differences in Ki-67 LIs between different 
clinical outcomes. Receiver operating characteristic (ROC) curve analyses were applied to 
broadly approach a distinction between Ki-67 values of cases with complete response to 
therapy and those without it. The possible connection between ER receptor status and type of 
tumor regression (omitting the cases with partial regression) following neoadjuvant 
chemotherapy was also analyzed applying Fisher’s exact test. All analyses were performed 
with the statistical software package SPSS 15.0 for Windows (SPSS Inc., Chicago, Illinois). 
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4. RESULTS 
 
4.1   REPRODUCIBILITY AND CORRELATION ANALYSIS OF THE KI-67 
EXPRESSION LEVELS BY TYPES OF ANTIBODY AND INVESTIGATORS 
 
Thirty core-biopsy samples of breast cancer patients were analyzed. The mean ± SE age 
of the population was 46 ± 2 (range: 26–70) years. Samples included 28 invasive ductal 
carcinomas, and 2 invasive lobular carcinomas. Altogether 270 evaluations were made by 3 
independent pathologists with expertise in breast pathology (CG, VA, CE), and these were 
repeated a second time to better assess intraobserver variability.  Mean±SE Ki-67 LI values of 
the first and the second evaluations by the 3 pathologist were 45±2%, 52±2% and 56±2% for 
the SP6, B56 and MIB-1 antibodies, respectively.  
Spearman’s rank correlation was used for comparison of the different observers and 
antibodies. Each analysis was performed on the first and the second evaluation separately and 
then combined. Interobserver comparisons for the dual (combined) evaluation suggested that 
the correlation between ratings was good to excellent (coefficients ranging between 0.74 and 
0.91, p<0.0001). Interantibody comparisons yielded coefficients ranging between 0.8 and 0.92 
(p<0.0001) suggesting excellent interantibody correlation. Pearson’s coefficients ranged from 
0.73 to 0.91 (p<0.0001.) for the pairs of observers and from 0.79 to 0.93 (p<0.0001) for the 
pairs of antibodies, suggesting similarly good to excellent correlation. When all 18 ratings (3 
observers, 3 antibodies, twice) of the 30 cases were considered, the majority determined 
allocation of the cases was as follows: 1st quarter (0-25% Ki-67 LI) – 5 cases; 2nd quarter – 
12 cases; 3rd quarter – 6 cases; 4th quarter – 7 cases. Only 2 tumors had all rating falling into 
the same quarter: one belonged to the lowest, one to the highest proliferation group. For the 
other categorization, the majority classifications suggested that 3 cases had a Ki-67 LI not 
greater than 15%, 4 cases fell into the 16-30% LI category and 23 cases had a high 
proliferation with a LI>30%. All the 10 cases with 100% agreement in the classification 
belonged to the highly proliferative tumors. 
On the basis of the kappa values, the reproducibility of the Ki-67 LI values by quarter 
category distribution was generally moderate to substantial in the lowest and the highest 
quarters, but was only slight to fair in the middle quarter categories (Table 3 part A). 
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Table 3 Kappa values per observer and antibody according to classification into 4 
quarter categories (A) and 2 cut-off determined 3 categories (B) 
 
 
A 0-25% 26-50% 51-75% 76-100% Overall 
ALL* 0.47 0.24 0.14 0.52 0.34 
Observer 1 0.63 0.32 0.15 0.51 0.39 
Observer 2 0.45 0.13 0.03 0.54 0.3 
Observer 3 0.58 0.38 0.28 0.55 0.44 
MIB-1 0.51 0.24 0.15 0.54 0.36 
B56 0.48 0.27 0.11 0.52 0.35 
SP6 0.44 0.2 0.15 0.57 0.32 
 
 
B 0-15% 16-30% >30% Overall 
ALL* 0.42 0.19 0.52 0.39 
Observer 1 0.61 0.38 0.61 0.52 
Observer 2 0.42 0.13 0.51 0.37 
Observer 3 0.4 0.24 0.54 0.41 
MIB-1 0.35 0.26 0.56 0.41 
B56 0.38 0.1 0.53 0.37 
SP6 0.45 0.29 0.56 0.44 
 
 
 
* All refers to the 18 assessments of the same cases with 3 antibodies, by 3 observers, 
twice. The remaining values are based on 6 assessments each: for the observers 3 antibodies, 
twice; for the antibodies 3 observers, twice. 
 
 
This resulted in overall kappa values reflecting only fair reproducibility both for given 
observers and for given antibodies. The same statement can be made after the evaluation of 
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the dual assessment of all cases with all antibodies (18 evaluations per case). Pairwise 
weighted kappa values showed somewhat better interobserver consistency (range 0.43-0.75) 
reflecting moderate to substantial reproducibility. When looking at the distributions 
determined by the 15% and 30% cut-off values, the reproducibility of the highly proliferative 
classification remained moderate/substantial, but the low and intermediate proliferation 
groups were less reproducible (Table 3 Part B).  Pairwise weighted kappa values ranged 
between 0.3 and 0.78 for these categories and also suggested fair to substantial 
reproducibility. The better reproducibility reflected by the weighted kappa values indicate that 
inconsistent categorizations were often one category away from each other, i.e. low 
proliferation rates were unlikely to be ranked as high and vice versa. 
Similar statements can be made concerning the intraobserver agreements determined for 
all 90 immunostained samples (Table 4): tumors with a high and a low Ki-67 LI can be more 
reproducibly be identified than tumors falling into the intermediate (26-75% or 16-30%) 
range both on the basis of quarter based four-tiered distribution or the two cut-offs defined 
three-tiered distribution. However, differences between observers can also be identified. 
Observer 2 demonstrated somewhat worse performance than the other two. This observer had 
only 47% identical categorizations on the basis of the four-tiered categorization (in contrast to 
57% and 58% for the two others) and 63% identical categorizations on the basis of the three-
tiered classification (in contrast to 80% and 83% for the two others). 
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Table 4 Kappa values reflecting intraobserver reproducibility of the classification of Ki-
67 LIs into 4 categories (A) or into 3 categories (B) 
 
 
A 0-25% 26-50% 51-75% 76-100% Overall 
Observer 1 0.76 0.34 0.13 0.51 0.42 
Observer 2 0.4 0.01 0 0.61 0.26 
Observer 3 0.55 0.32 0.3 0.51 0.41 
 
 
B <16% 16-30% >30% Overall 
Observer 1 0.64 0.5 0.69 0.61 
Observer 2 0.37 0.07 0.57 0.36 
Observer 3 0.45 0.32 0.64 0.5 
 
 
The two way ANOVA has confirmed the fact that Observer 2 rated the cases 
significantly lower than the two others (p=0.004 first observations and p=0.008 second 
observations), and also suggested that one antibody (SP6) also resulted in significantly lower 
mean Ki-67 LI values (45.2 % overall versus 52.3% for B56 and 55.7% for MIB-1; p=0.017 
first round observations and p=0.01 second round observations). 
The individual evaluation patterns were also evaluated. It turned out that all observers 
aimed to quantify the area with the highest number of stained cells; very weekly, faintly 
staining nuclei were generally discarded. All observers estimated the proportion of positive 
cells in relation to approximately 100 tumor cells of the chosen area, but there were also 
differences in the way of estimating this proportion. Observer 1 counted 100 cells and 
recounted the number of positive nuclei in the same 100 cells. Care was taken to keep in mind 
the tumor structures included and excluded in the 100-cell-containing area to allow the count 
of the positive nuclei in the same 100 cells. Observer 2 counted 10 tumor cells to get an 
impression of the area these cells occupied and included an area of tumor cells ten times 
greater, than this basic count, and finally effectively counted the number of positive nuclei in 
the area estimated to contain 100 tumor cells. Observer 3 made an approaching guess in a 
larger area of the hot spot, than counted the proportion of stained nuclei in 20 or 30 cells, and 
26 
 
multiplied by 5 or 3 to get a percentage estimate. For cases with a very high LI a reverse 
count was made, by evaluating the unstained nuclei. Therefore the used methods were 
comparable in some respects, but differed in their details of cell counting. All were generally 
based on the different approximations of the proportion of nuclear staining in relation to 100 
cancer cells in hot spot areas, and neither tried to better estimate this ratio by counting 1000 
cells as suggested by some authors [10, 34]. 
 
4.2   INVESTIGATION OF A STANDARDIZED, PARTIALLY DIGITALIZED 
COUNTING METHOD  
 
The patients and core biopsy samples were identical with the set studied in part 1 (under 
headings 3.1 and 4.1) and the basic characteristics were described there.  
Altogether 720 evaluations were made by 4 independent pathologists with special 
interest in breast pathology (GC, AV, EC, BK). Mean±SE estimated and counted Ki-67 LI 
values provided by the 4 pathologists are shown in Table 5.  
 
Table 5 Mean±SE Ki-67 values obtained by estimation and calculation for each 
investigator 
 
OBSERVERS 
MEAN±SE CALCULATED 
VALUES 
MEAN±SE ESTIMATED 
VALUES 
GC 53.12±2.54 59.56±2.85 
AV 54.40±2.69 61.28±3.09 
EC 63.94±2.53 63.94±2.95 
BK 56.04±2.45 61.72±2.91 
 
 
The calculated Ki-67 LI was based on the assessment of an average of 75-91 cells. 
There were no major differences in the cells counted from the same set of digital images by 
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different investigators. The range of cells counted on the grid marked images was 9 to 194, as 
a single image with the same grid was used for each tumor and core biopsy. 
Ki-67 values for individual cases and individual observers are presented in Figure 5. 
  
 
 
Figure 5 Proportion of Ki-67 stained cells as determined by different investigators. 
Cases 1-30 are samples immunostained with the MIB-1 antibody, cases 31 to 60 are those 
stained with B56 and cases 61 to 90 are the ones stained with SP6. 
A: Calculation based values; B:  Estimation based values. 
 
The graphs demonstrate a very good overlap between investigators, both for the 
estimated and the counted Ki-67 values. Furthermore, the similar shapes of the graphs for the 
estimated and calculated Ki-67 values suggest a good overlap between the two methods of 
assessment. These impressions were also substantiated by the statistical analyses.  
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Good to excellent correlation was observed both with the Pearson’s and the Spearman’s 
methods when comparing the estimated and the calculated Ki-67 values of each investigator 
when analyzing all antibodies (90 cases per observer) (Table 6).  
 
Table 6 Intraobserver correlations between the estimated and the calculated Ki-67 LIs 
for each investigator. 
 
OBSERVERS GC AV EC BK 
Pearson’s coefficient 0.904 0.907 0.899 0.920 
Spearman’s coefficient 0.898 0.915 0.886 0.925 
 
 
 
The 90 assessments (all antibodies included) of each pair of investigators were also 
compared both for the estimated and the calculated Ki-67 LIs. The interobserver correlation 
coefficients demonstrate an excellent correlation (Table 7). 
Similar correlation analyses were repeated in case of each antibody, one by one (i.e. 
only 30 cases with the same antibody per observer), in order to see whether different 
antibodies were associated with different correlations. To compare the effect of the antibodies 
on the intraobserver correlation of estimated and calculated Ki-67 LIs, as a basic approach, 
the 4 correlation coefficients by observers were averaged. In case of SP6 the mean±SE values 
of the Person’s and Spearman’s correlation coefficients for the estimated Ki-67 LIs were 
0.855±0.044 and 0.857±0.035, respectively. These values were 0.922±0.004 and 0.926±0.008 
in case of B56, and 0.904±0.012 and 0.879±0.026 in case of MIB-1, respectively (Figure 6). 
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Table 7 Interobserver correlations for both the estimated (yellow cells) and the 
calculated (white cells) Ki-67 LIs 
 
 
  GC AV EC BK 
GC 1 0.927 0.927 0.930 
AV 0.957 1 0.909 0.960 
EC 0.966 0.954 1 0.964 
BK 0.958 0.972 0.979 1 
 calculated and estimated  
(Pearson)(A)                                  
 
 
 
 
 
 
Figure 6 Intraobserver correlation (all observers) by antibody type, as reflected by 
mean coefficient values 
These results suggest that SP6 might have at least a trend for a slightly weaker intra-
observer correlation, than the others. With interobserver analyses by antibody type, 
  GC AV EC BK 
GC 1 0.929 0.922 0.927 
AV 0.951 1 0.916 0.955 
EC 0.964 0.956 1 0.956 
BK 0.955 0.976 0.977 1 
calculated and estimated 
(Spearman)(B) 
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comparing the calculated values (6 pairs of investigators) in case of SP6, the mean±SE values 
of correlation coefficients derived from Pearson and Spearmen tests were 0.871±0.044 and 
0.881±0.039, respectively. In case of B56 these values were 0.967±0.005 and 0.947±0.005, 
respectively, while for MIB-1 they were 0.957±0.006 and 0.960±0.006, respectively. For the 
estimated values, the following results were found using Pearson and Spearman tests, 
respectively (mean±SE): 0.942±0.008 and 0.943±0.009 for SP6, 0.947±0.008 and 
0.962±0.006 for B56, finally 0.926±0.012 and 0.896±0.013 for MIB-1 (Figure 7). 
 
 
 
Figure 7 Interobserver correlation (all observers) by antibody type, as reflected by 
mean coefficient values (calc: calculated; est: estimated) 
 
 
These results also suggest that SP6 might be associated with less concordance between 
observers, but only in case of the calculated Ki-67 LIs while in case of MIB-1, the estimation 
of Ki-67 LIs showed lower correlations.   
When all Ki-67 values (30 cases stained with 3 antibodies, i.e. 90 values per observer) 
estimated by eyeballing were considered, reproducibility of the proliferative activity was 
substantial both for the classification into 4 equal quarters (kappa: 0.68) and the classification 
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into three categories (kappa: 0.65). The kappas were 0.67 and 0.73, respectively in case of the 
calculated Ki-67 values, all corresponding to substantial agreement. 
Examining the antibodies one by one, using four categories and estimated Ki-67 values, 
the kappas were 0.65, 0.69 and 0.64 for the MIB-1, B56 and SP6 antibodies, respectively. For 
the three-tiered estimated Ki-67 categories, kappa values were 0.59, 0.69 and 0.67, 
respectively. Analyzing the calculated Ki-67 LIs, kappas were 0.66, 0.71 and 0.65, 
respectively for the four categories and 0.90, 0.60 and 0.69, respectively for the three 
categories. The agreement of the Ki-67 LIs gained by different antibodies was therefore 
almost always substantial, with two instances suggesting moderate reproducibility but falling 
just short of the substantial agreement category, and one instance with an almost perfect 
agreement. 
The mean time to evaluate the Ki-67 LI on a single digital image was calculated on the 
basis of the time used for the investigation of 30 biopsy samples stained by a given antibody. 
By eyeballing this time ranged between 18 and 50 seconds per investigator, and this range 
was between 90 and 180 seconds when the cells were counted, and the Ki-67 LI was derived 
from the calculated proportion of stained and all tumor cells. 
 
4.3   EVALUATION OF THE DISTRIBUTION OF KI-67 LIs IN BREAST 
CARCINOMAS DIAGNOSED AT DIFFERENT INSTITUTIONS 
 
Altogether 19 departments related to the European Working Group for Breast Screening 
Pathology referred data on 1782 tumors, of which 73 from one centre had to be excluded 
because of categorical Ki-67 values (<15, 15-30, >30 per cent LI), leaving 1709 tumors for 
further analysis. Ki-67 staining was automated in 15 of the laboratories providing the results, 
and MIB-1 antibodies were used in the majority (n=14). The antibody dilutions varied 
between 1:20 and 1:500. Full tumor sections were used to establish the Ki-67 LI in 72% of the 
cases (n=1233). Data on 1473 tumors were the results of routine staining in consecutive breast 
carcinomas, whereas data on 309 tumors (from 4 departments) were consecutive staining of 
nonconsecutive cases (in these departments not all breast cancers were stained, but all stained 
cases of a given period were included). Eleven of the 19 centers / pathologists reporting data 
(1009 tumors) counted the Ki-67 LI, whereas 8 of them used an eyeballing based estimation 
(773 tumors). Some method of rounding of the obtained Ki-67 LI values was used in the case 
of 873 tumors, and no rounding of the values was made for 909 tumors. Five pathologists 
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assessed the proportion of staining in 100 cells, 3 in 200 cells, 1 in 300 cells, 1 in 500 cells 
and 1 in 1000 cells. Hot spots were included by 18/19 pathologists and were the only areas 
assessed when present in the practice of half of them. The recommendations of the 
International Ki-67 in Breast Cancer Working Group were known in 16 of the 19 laboratories, 
but were adhered to in only a minority. Overall, the median Ki-67 LI of the 1709 breast 
carcinomas analyzed further was 17% with a mean±SD of 23.4±21% (range 0% to 100%). 
When arranged in quartiles or terciles, the mean±SD Ki-67 LIs (%) for quartiles and terciles 
were 4.2±2.1, 12.4±2.4, 23.5±4.2, 53.6±18.5 and 5.6±3.1, 17.4±4.3, 47.3±19.4, respectively. 
The lower half had a mean±SD LI of 8.3±4.7%, whereas the upper half was characterized by 
a mean±SD of 38.6±20.1%. The Ki-67 LI values were higher in cases in which the mitotic 
score component of the combined histological grade [35] were higher. Each score was 
characterized by the following respective median and mean±SD Ki-67 LIs: score 1: 10 and 
13±12; score 2: 23 and 27±18; score 3: 45 and 48±24. The Ki-67 LI values showed clustering 
at numbers ending with 5 or 0, 1084 values (63%) clustered at zeros and fives and 653 values 
clustered at zeros (38%) (Figure 8). 
As such clustering is to be expected with estimated values, the data were divided 
according to the method of evaluation (counting versus estimation) (Figure 9) and the subset 
of values obtained from consecutive tumors with counting of the stained cells and no 
rounding of the values (n=600) was separately analyzed. Similar clustering of Ki-67 LI values 
was present in 199 (33%) and 119 (20%) cases, respectively (Figure 10). 
As Ki-67 LI is often used to tailor treatment in ER-positive and HER2-negative tumors, 
this subset has been analyzed separately. The median Ki-67 LI was 14% (mean±SD: 17±15) 
in the 1248 patients having this type of carcinoma. Clustering of the values was seen in both 
the subsets assessed by counting (n=745) and estimation (n=503) (Figure 11). 
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Figure 8 Clustering of Ki-67 LI values in 1709 breast cancers (Ki-67 values on axis x, absolute numbers on axis y) 
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Figure 9 Ki-67 LI values according to the method of evaluation (Ki-67 values on axis x, absolute numbers on axis y)(Counted: red; 
estimated: green) 
 
Figure 10 Clustering of Ki-67 LI values in 600 breast cancers in which the LI was determined in a consecutive series of tumors by counting 
without rounding the values (Ki-67 values on axis x, absolute numbers on axis y) 
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Figure 11 Clustering of Ki-67 LI values in 1248 ER-positive and HER2-negative breast cancers (Ki-67 values on axis x, absolute numbers 
on axis y) (Counted: red; estimated: green)
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4.4   DIFFERENT METHODS OF PRETREATMENT KI-67 LABELING INDEX 
EVALUATION IN CORE BIOPSIES OF BREAST CANCER PATIENTS TREATED 
WITH NEOADJUVANT CHEMOTHERAPY AND THEIR RELATION TO RESPONSE 
TO THERAPY 
 
Altogether 1350 evaluations were analyzed in our study (as one investigator did not take 
part in the first count, i.e. Method 1).  The overall mean value of the Ki-67 LI (with all 
assessment methods, antibodies and observers considered) was 54.22 (95% CI: 53.13-55.31). 
According to the statistical analyses, values of Ki-67 were significantly different in the 
different regression groups: values of the group without regression were significantly lower 
than the values of the group showing complete regression (p<0.0001). The mean values of Ki-
67 LI taking into account all methods of assessment were 66.61 (95% CI: 64.71-68.50), 51.32 
(95% CI: 49.43-53.21) and 44.72 (95% CI: 42.83-46.62) for the groups with complete, partial 
and no regression, respectively. 
The two way analysis of variance using the methods of evaluation and the response 
categories as factors showed significant differences in mean Ki-67 values according to both 
factors. The mean Ki-67 value was the lowest in Method 1 and highest in Method 3. Mean 
Ki-67 LI values were 46.63 (95% CI: 44.21-49.05), 54.62 (95% CI: 52.52-56.72), 61.59 (95% 
CI: 59.49-63.69) and 54.04 (95% CI: 51.94-56.17) in case of Methods 1 through 4, 
respectively.  
We found similar results after taking the clinical response into consideration. Mean 
value of Ki-67 LIs by Method 1 were 58.72 (95% CI: 54.53-62.92), 46.39 (95% CI: 42.19-
50.59) and 34.78 (95% CI: 30.58-38.98) in case of complete, partial and no regression, 
respectively, whereas these values were 77.18 (95% CI: 73.54-80.18), 56.59 (95% CI: 52.95-
60.13) and 51.00 (95% CI: 47.37-54.64), respectively with Method 3. 
Figure 12 remarkably illustrates that the red and blue fields representing the mean Ki-67 
LIs of cases with pCR and no regression, respectively are best separated from each other in 
case of Method 3, the estimation on single digital images and this is in accordance with the 
mean Ki-67 LIs described above. It is also clearly demonstrated that the yellow fields, which 
show partial regression are mostly located between the red and blue fields, slightly closer to 
the blue ones; sometimes they are fused (green). These patterns can be observed in case of all 
investigational methods, observers and antibodies. 
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Figure 12 Mean Ki-67 LIs gained by four different evaluation methods by 4 observers 
and 3 antibodies in the different categories of tumor regression after neoadjuvant 
chemotherapy. Blue fields represent values of tumors with no regression, the yellow ones are 
for tumors with partial regression and the red ones for those with pathological complete 
regression. The green color reflects the fusion of blue and yellow for instances when the mean 
values of partial regression and no regression fall in the same field. Each colored field 
represents the mean Ki-67 LI value of ten cases in one of the three groups (no regression, 
partial regression and complete regression). GC, AV, EC, BK reflect the observers and MIB-
1, SP6, B56 the antibodies. The scale of the figure is by 5%, i.e. each field represent a range 
of values with 5 integers from 1-5 to 96-100.  
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By applying an ROC curve analysis to the mean Ki-67 data, the distinction between 
cases showing complete regression versus cases showing no regression (and omitting the 
cases with partial regression) on the basis of Ki-67 values (gained by any method) gives an 
area under the curve (AUC) of 0.969, whereas comparing complete regression values with the 
cases with partial regression and those showing no regression lumped together, the AUC turns 
to 0.93 (Figure 13).  
 
 
Figure 13 ROC curve derived from all average Ki-67 values (all methods, observers 
and antibodies) as predictors of the group with pCR and those without it (partial response and 
no response together) 
 
 
 
Here the suggested best cut-off value to predict complete regression would have been 
around 56% LI (sensitivity: 0.89; specificity: 0.81).  
Figure 14 gives an insight into the distribution of individual Ki-67 LIs behind the mean 
values shown in Method 3 related part of Figure 12.  
 
39 
 
    5% 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 
M
eth
o
d
 3
 
GC 
MIB1                                                                                                                         SP6                                                                                 
B56                                                                                                     
AV 
MIB1                                                                                 SP6                                                             B56                                                                                 
EC 
MIB1                                                                                                     SP6                                                                                 
B56 
                                                                                                                                            
BK 
MIB1                                                                                                     SP6                                                                                 
B56                                                                                                      
Figure 14 Individual Ki-67 LI values for Method 3 (estimation on representative digital 
images). Blue fields represent values of tumors with no regression, the yellow ones are for 
tumors with partial regression and the red ones for those with pathological complete 
regression. Each colored field represents a case with a given Ki-67 LI. GC, AV, EC, BK 
reflect the observers and MIB-1, SP6, B56 the antibodies with 30 cases falling in each of the 
assessments. The scale of the figure is by 5%, as the estimation was done in steps of 5% 
precision. 
  
 
Although the mean values shown in Figure 12 are obviously higher (more to the right) 
for cases with pCR (red fields) than for the rest of the cases, it is clear that the individual 
cases show considerable overlaps. Although most red fields fall to the right and above 50%, 
there are a few blue and yellow fields (representing no regression and partial pathological 
response, respectively) falling among the red fields and a few red fields falling among the 
other colors and below 50%. Similar overlaps could have been represented for all methods 
investigated. 
According to the Fisher’s exact test cases showing complete pathological regression 
were more likely negative for ER receptor immunohistochemistry (p=0.024). 
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5. DISCUSSION 
 
Proliferation has been proposed as an important prognosticator of breast carcinomas, 
and the Ki-67 LI has been implied as a factor enabling a distinction between tumors with a 
high and a low proliferation. On this basis, Ki-67 has been used in various settings including 
the addition of adjuvant chemotherapy to hormonal therapy in the treatment of hormone 
sensitive breast carcinomas [St. Gallen 2009], the distinction between luminal A and luminal 
B subsets of estrogen receptor positive and HER-2 negative carcinomas [36] or the distinction 
between histological grade 2 carcinomas with an outcome similar to grade 1 or grade 3 
cancers [34].  
Therefore, the reproducibility of Ki-67 LI is important. Our results suggest that 
interobserver reproducibility of the Ki-67 LI may only be fair in everyday pathology practice, 
although the correlation between assessments by different observers or using different 
antibodies is good or excellent. This may cast some doubt about the general usefulness of this 
marker in its present state. The data also suggest that the classification of tumors into low and 
high proliferation categories is better (moderate to substantial) than that of tumors with an 
intermediate proliferative activity. This proved true both for cut off values of 25 and 75 per 
cents (per equal quarters assessment) and for cut-offs at 15 and 30 per cents as proposed by 
the St Gallen experts’ consensus in 2009 [25]. This may also mean that the range where the 
distinction is clinically important is characterized by better reproducibility. We also noted a 
rather consistent intraobserver reproducibility variation. The kappa values relating to 
Observer 2 were consistently lower than the values of the two other observers, although the 
high and low proliferation categories had higher kappa values even for this observer. This 
may reflect the differences in the technique of evaluating the Ki-67 LI. All observers made 
the LI estimation on the basis of approximately 100 cells in a hot spot area. Observer 1 
counted a real percentage values by counting 100 cells and recounting the positive (or at times 
the negative) nuclei in the same cells. Observer 2 approximated the area containing 100 cells 
by first delineating an area with one tenth of this population, and then counted the positive 
tumor cell nuclei in this area. Finally, observer 3 counted the proportion of immunostained 
tumor cell nuclei in one fifth or one third of the area and then extrapolated this result to 100 
cells. The two latter techniques spare time. Interestingly, Observer 3 had kappa values very 
comparable with those of Observer 1. The most “time consuming” evaluation, that of 
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Observer 1, took 3 to 4 minutes per case, and 90 to 100 minutes for scoring the 30 cases in the 
series once. 
MIB-1 is generally used in everyday practice to determine the Ki-67 LI on formaline 
fixed and paraffin embedded material. This antibody was generated using recombinant 
technology and reacts with the immunodominant area of the Ki-67 nuclear antigen [37]. B56 
is also directed against the same area and also represent an IgG1 mouse monoclonal antibody. 
Although SP6 is a rabbit monoclonal antibody directed against the C-terminus of the Ki-67 
protein, it has recently been reported to correlate well with MIB-1 staining [38]. SP6 showed 
significantly lower mean Ki-67 LI values than the other antibodies in both the first and the 
second round assessments, but this did not influence reproducibility. In keeping with the 
above, the three antibodies used had very similar overall kappa values reflecting fair to 
moderate reproducibility for the whole range of the cases.  
Several studies casted doubts about the reproducibility of Ki-67 LI evaluation [1, 29]. 
Although the St. Gallen International Expert Consensus on the Primary Therapy of Early 
Breast Cancer (2009 and 2011) recommended an accurate methodical proceeding (e.g. 
counting 1000 tumor cells), and the International Ki67 in Breast Cancer Working Group also 
suggested a similar approach (Table 1) [18], the everyday use and ability to follow this 
recommendation is questionable. As suggested in the present series, even intra-laboratory 
differences in assessment may exist; pathologists may tend to use less time-consuming 
methods. Despite only fair overall reproducibility of the Ki-67 LI into categories of different 
proliferative activity, the results between the observers and the antibodies were at least 
moderately correlated, and the identification of tumors with the highest proliferation was 
better (moderate to substantial), than that of tumors with intermediate proliferation according 
to both approaches tested. (Although this is the result of a universal statistical occurrence, we 
should be more aware of this phenomenon in clinical decision making, and acknowledge that 
intermediate or “grey-zone” categories are generally less reproducible than low and high 
value categories, as exemplified by our data). It therefore seems that clinically important 
categorizations (high proliferation versus non-high) can be more consistently made even with 
the methods described, although it is believed that substantial to excellent reproducibility 
would make the use of Ki-67 as a biomarker more confident. 
Although an international consensus recommends the examination of at least 500, but 
optimally 1000 cells for deriving the Ki-67 LI (Table 1) [18], this practice is rarely followed, 
and counting about 100 cells or estimating the overall stained proportion of tumor cells are 
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common methods of assessing proliferation as suggested by the data provided by pathologists 
from different European institutions in part 3 of this thesis. Indeed, 13 out of 19 participants 
followed these latter practices, i.e. estimated the proportion of stained nuclei or produced the 
percentage of stained cells on the basis of 100 cells. The lack of time is one of the most 
important factors deviating from the counting of high number of cells. The presented results 
regarding digital image analysis support that by choosing a limited area of high proliferation 
from the tumor as represented by a digital image, and by helping to choose which cells to 
count with a grid, improves reproducibility of determining the Ki-67 LI. Indeed, the 
interobserver agreement on the Ki-67 LI reached on the real slides of the same cases and 
derived on the basis of about 100 cells from the area with the highest staining proportion was 
only fair on the basis of the overall kappa values <0.4 [39], but changed to substantial (overall 
kappa >0.6) for the digital images. Such an improvement in reproducibility was achieved by 
counting somewhat less cells on average than the 100 cells in the previous investigation, but 
the present study did not assess how many cells needed to be evaluated to reflect the 
proliferative activity of a tumor on the basis of a needle core biopsy, it only concentrated on 
reproducibility issues. It may well be, that several digital images would be required to reflect 
tumor proliferation. We expect similarly acceptable reproducibility with 2, 3 or more images. 
On the dark side of such an improvement, we must accept a loss in time. Making digital 
images of given areas of a tumor histology slide and adding a standard grid to the image may 
be fast in some settings, but may also take too much time to be affordable. The evaluation 
itself is also somewhat time-taking, requiring 2 to 3 minutes per digital image, depending on 
the cell density. Therefore, the finding that a rough estimate of the stained proportion of tumor 
cells may be as reproducible as the calculated LI is of interest. Varga et al. in a very carefully 
designed study showed, that better reproducibility could be achieved by estimation than by 
accurate counting: there was much less deviation of data from a central mean value when the 
observers estimated the proportion of stained cells than when they counted it [40]. Our results 
are in keeping with this observation, as good to excellent correlation was found between the 
estimated and the counted Ki-67 LI values and the overall kappa values also suggested 
substantial reproducibility for the eyeballing based estimation of the Ki-67 LI. Eyeballing 
obviously require less time, as supported by our data. 
It is also important to highlight that our findings were retrieved on core-biopsy samples. 
Core biopsies might not always contain 1000 tumor cells for counting as non-tumor tissue 
may be common part of such specimens. Of the different factors potentially influencing the 
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Ki-67 LI, tissue fixation, heterogeneity of different tumor areas, heterogeneity of nuclear 
labeling intensity are infrequent in such small samples, and this may improve reproducibility, 
although, on the other side, the representative nature of a small sample may be questionable. 
For example, Romero at al showed significant differences between core biopsy and surgical 
sample proliferation values, what may confirm our supposition that core biopsy specimens 
allow better reproducibility on the basis of a smaller sample with lesser variability [41]. 
Beside reproducibility analysis, it seemed to be interesting and informative to evaluate 
the distribution of Ki-67 LIs in breast carcinomas diagnosed at different institutions. The 
collected data demonstrate that the distribution of Ki-67 LI clusters at lower values (the 
median proportion of Ki-67 stained proliferative cells was 17% for all tumors and 14% for the 
ER-positive and HER2-negative subset), which reflects a tumor biology related influence on 
the distribution of the values. However the Ki-67 LI values also cluster at numbers ending 
with 5 or 10, which is a human evaluation related item.  
Several factors influencing the determination of Ki-67 LI have been mentioned 
previously. In this series based on daily pathological methods and practices, the human factor 
is reflected by the predilection for some LI values being more common than others in both the 
low and the high proliferation ranges. As the methods of evaluation are somewhat 
heterogeneous and the interobserver reproducibility of evaluating the proportion of Ki-67 
labeled tumor cells is less then optimal, it is not surprising that the suggested cut-offs are also 
variable. Any cut-off value will separate higher and lower proliferative groups of tumors, but 
generalization of cut-off values from a specific study [25, 26] carries in itself a potential 
misclassification of some patients.  
Published data suggest that the reproducibility of Ki-67 stained cell evaluation is not 
worse when the proportion is estimated rather than calculated after meticulous counting [40]. 
Therefore the clustering of the values illustrated on the figures of this report (which can 
probably be generalized) suggest that if a cut-off between highly proliferating tumors and 
tumors with low proliferation is to be used to allow a selection of patients at higher risk of 
relapse and as a factor influencing the application of systemic chemotherapy, it should 
consider realistic distribution of the cases, and should probably be an inclusive or non-
inclusive number ending with 5 or 0 (like 10%, 15% or 20%), or more preferably ending with 
0 (like 10% or 20%). Taking into consideration the distribution of Ki-67 values presented in 
this study in comparison to previously presented cut-offs, some existing recommendations for 
Ki-67 LI in therapeutic decision making (e.g. the previous St Gallen recommendations using a 
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cut-off of <14% for determining luminal A tumours by IHC [26]) do not seem to be 
reasonable. In line with our findings, the latest St Gallen recommendations have appeared and 
mention an inclusive 20% cut-off for discriminating between luminal A and HER2-negative 
luminal B breast carcinomas [28]. Different cut-offs may be generated for different clinical 
purposes. 
As mentioned previously, the Ki-67 LI has prognostic value in breast cancer and may 
indicate the need for additional chemotherapy in special cases. Cytotoxic therapy acts on 
proliferating cells, therefore it would be very logical to hypothesize that tumors with a higher 
baseline proliferation may better benefit from chemotherapy than those with a low baseline 
proliferation. In keeping with this theoretical approach, a better response to neoadjuvant 
chemotherapy was reported in tumors with high baseline Ki-67 LI [8, 21, 42, 43]. In contrast, 
tumors with a high Ki-67 LI showed similar response rate (77%) to chemoendocrine therapy 
than those with a low Ki-67 LI (81%) in a retrospective series from the Royal Marsden 
Hospital [44]. It is also likely that Ki-67 applied as a dynamic marker (i.e. taken as a baseline 
value and also during neoadjuvant therapy) may better predict the response and the outcome 
of disease [21, 42, 45], but multiple biopsies are not always easy to obtain. Our results 
displayed in Figure 12 show that breast cancers showing pCR consistently had a higher mean 
Ki-67 LI than those not responding or showing only partial pathological response whatever 
the method of evaluation or the antibody used were or whoever the observer was. Although 
this difference was seen among the small groups showing regression, looking into the details 
demonstrates that the regression of individual cases of breast carcinoma cannot be precisely 
predicted (Figure 14), and prediction on the basis of high versus low Ki-67 LI does not work 
for the individual cases. The only thing that can be stated is that tumors with higher Ki-67 LIs 
are more likely to regress completely, independently of the method of evaluation.  
The methods compared in this study had different reproducibility [39, 46]. Although a 
good to excellent correlation was found between the results gained by different methods, 
antibodies and observers, the interobserver and intraobserver reproducibility of the everyday 
practice based counting on glass slides (Method 1) was only fair to moderate. Reproducibility 
of the Ki-67 LI has improved when the field to be assessed was limited to a digital image, 
chosen to represent the highest proliferation in the core biopsy sample (Method 2) [39, 46]. 
Interestingly, reproducibility was not worse when the proportion of stained cells was only 
estimated (Method 3) rather than counted (Methods 1 and 2). This is in keeping with the 
results of the carefully designed study by Varga et al, cited earlier: estimation does not seem 
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to be worse than counting, it may even be better [40]. This suggests that the simple approach 
of estimating by eyeballing has also diagnostic value, and may be better received by the 
pathological society as a simple and fast method, taking 4 to 12 times less time than counting 
[39, 46]. The daily use of estimating rather than counting the Ki-67 LI by at least some 
pathologists was also highlighted in the series evaluating the distribution of Ki-67 LI values in 
different pathology departments [47].  
Although all of our study cases received neoadjuvant chemotherapy on the basis of 
locally advanced stage according to general practice and recommendations, biological 
markers, including those reflecting a high proliferation rate might be more suitable to select 
patients with potential benefit from this treatment. Pathological complete regression is 
associated with better prognosis [48, 49], and tumors achieving pCR have a higher mean Ki-
67 LI than those which do not achieve pCR, in keeping with earlier works [8, 21, 42, 43]. 
However, proliferation alone is not sufficient to predict the response to neoadjuvant 
chemotherapy [43], as demonstrated by Figure 14, and it is also a matter of debate what cut-
off value should separate tumors with high and low Ki-67 LIs. In this respect, Figure 12 
seems useless, and suggests that depending on the methods, antibodies and observers, 
different cut-offs could be used for this purpose. Fasching et al used a >13% cut-off [8], in 
keeping with the value formerly suggested for the immunohistochemistry based separation of 
luminal A and luminal B carcinomas [26, 36]. As suggested by our analysis of the data 
relating to the distribution of Ki-67 LIs gained with the participation of members of the 
European Working Group for Breast Screening Pathology, the distribution pattern of 1709 Ki-
67 LI values had peaks at values ending with 0 or 5, and therefore an inclusive or non-
inclusive cut-off ending with these values would seem more realistic [47], and independently, 
the latest St Gallen recommendations have happily adopted a 20% cut-off in keeping with this 
result. Figure 12 would suggest that with most of the methods included, a cut-off of 50% 
would delineate high proliferation, and the ROC curve analysis also supports a similar value 
(i.e. 55%) but the analysis of the distribution pattern of Ki-67 LIs suggests that only a 
minority of breast cancers would fall into this category, as the median Ki-67 LI of the large 
cohort was 17%, whereas the estrogen receptor-positive cases had a median of only 14% [47]. 
Therefore, the small subset of locally advanced breast cancers analyzed in the present work 
would fall into the higher end of the Ki-67 LI values of a general breast cancer cohort, and 
might not be representative enough. The fact that the determination of the Ki-67 LI in the 
present analyses was concentrating on the most proliferative parts of the tumors represented in 
46 
 
the core needle biopsy samples rather than on both highly and less proliferating areas together 
may also partially explain these differences. These considerations would also counteract the 
determination of a cut-off value. Individual cases with high proliferation (e.g. Ki-67 LIs 
above 50%) would still have overlapping Ki-67 LI values with non-regressing tumors (Figure 
14). 
As to the best method, statistics do not allow to suggest that one of these methods is 
better than the other, they are just different from each other regarding to Ki-67 LIs. It seems 
obvious that Method 3 (the estimation made on the digital image taken from the area thought 
to represent the highest proliferation in the core biopsy sample) had substantial reproducibility 
[46], is fast and simple, and seems to separate responders from non-responders better than the 
other methods. However, individual cases would fail to follow the prediction even on the 
basis of this small sample. (The number of data evaluated in this study did not allow an ROC 
curve analysis of sufficient value to estimate the best cut-off value for this individual method.) 
Response to therapy is obviously a phenomenon depending on multiple factors of which the 
number of cells in the cycle is only one. For example, the predictive role of the hormone 
receptor status has also been widely investigated [8, 19-23]. A recent meta-analysis by 
Houssami also concluded that ER-negative tumors are more likely to achieve pCR [50]. The 
data of this small series are in keeping with this, since ER-negative tumors were more 
common in the pCR group than in the rest of the patients.  
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6. CONCLUSIONS 
6.1  Our results suggest that reproducibility of the Ki-67 LI is less than optimal even 
in core needle biopsies of breast cancer patients. However, the reproducibility of classifying 
tumors into a clinically more important highly proliferative category (like >15% or >25% or 
>30%) is better than that of the overall classification and is not very much influenced by the 
antibody used (at least true for the 3 antibodies tested).  
6.2  At present, the consistency of Ki-67 LI determination in the routine work of 
some (probably numerous) laboratories (including ours) does not allow error free therapeutic 
decision making on a yes or no basis. Our results also indicate that similar but slightly 
differing individual practices of Ki-67 LI evaluation by different observers may influence 
reproducibility, therefore reasonable standardization and the recommendation of a workable 
uniform method should be encouraged.  
6.3  The use of a simple digital technology, taking microphotographs of proliferating 
areas of breast cancers and adding a grid to the pictures to better delineate which cells to 
consider in the count makes possible for different investigators to examine the same area and 
the same cells when determining the Ki-67 LI. This can significantly improve reproducibility. 
We found that calculating the LI on the basis of such grid labeled digital images results in 
better reproducibility than the frustratingly low one found on the basis of counting stained 
cells on the histology slides of the same core biopsy specimens. 
  
6.4 Estimating the proportion of Ki-67 stained cells on the same digital images is not 
only faster than counting the stained and unstained cells, but also results in acceptable and 
substantial reproducibility and the estimated and counted values correlate strongly. Therefore 
estimation should not be considered an inadequate method of establishing the Ki-67 LI, 
simply because it is not based on objective numbers. 
 
6.5     On the basis of the distribution pattern of a larger series of Ki-67 LI values, some 
suggested Ki-67 LI cut-off values are not realistic, and it is proposed to select more realistic 
values ending with 0 or 5. 
6.6  Tumors achieving pCR after neoadjuvant chemotherapy have a higher mean Ki-
67 LI than those that achieve either partial pathological response or do not show regression. 
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This statement is true for all the 3 antibodies tested, all the 4 observers and all the methods 
evaluated. Therefore, the simplest methods of evaluating the Ki-67 LI by eyeballing rather 
than time-consuming counting could be a good alternative to assess the proliferation rate. 
Despite the association of a higher Ki-67 LI with pCR, a high Ki-67 LI alone is not sufficient 
to predict response to neoadjuvant chemotherapy, since other factors (including the ER status 
of the tumor) also influence the response to treatment.  
  
6.7      Based on our studies, different evaluation methods may require different cut-off 
values to distuingish between tumors with high and low proliferation, and identify tumors 
with a higher chance of regression following neoadjuvant chemotherapy. Our data do not 
allow the suggestion of any cut-off value. The estimation of a cut-off value would probably 
require a larger series of cases. 
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